Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Nov 16, 2014; 6(11): 541-548
Published online Nov 16, 2014. doi: 10.4253/wjge.v6.i11.541
Published online Nov 16, 2014. doi: 10.4253/wjge.v6.i11.541
Colorectal cancer surveillance in inflammatory bowel disease: A critical analysis
Devendra Desai, Division of Medical Gastroenterology, P D Hinduja Hospital, Veer Savarkar Marg, Mahim, Mumbai 400016, India
Nutan Desai, Department of Gastroenterology, Fortis Hospital, Mulund, Mumbai 400016, India
Author contributions: Desai D and Desai N contributed equally to concept and design, acquisition and interpretation of data and final drafting; both authors accepted the final draft.
Correspondence to: Devendra Desai, MD, DNB (Gastroenterology), Division of Medical Gastroenterology, P D Hinduja Hospital, Veer Savarkar Marg, Mahim, Mumbai 400016, India. devendracdesai@gmail.com
Telephone: +91-22-24447106 Fax: +91-22-24440425
Received: May 28, 2014
Revised: August 28, 2014
Accepted: September 16, 2014
Published online: November 16, 2014
Revised: August 28, 2014
Accepted: September 16, 2014
Published online: November 16, 2014
Core Tip
Core tip: There is an increase in the risk of colorectal cancer in patients suffering from inflammatory bowel disease. Recent studies have suggested that this risk may be decreasing. In view of the risk, colonoscopic surveillance is recommended in order to detect cancer early. Instead of using previous methods of colonoscopy and random biopsy, newer technology such as chromoendoscopy and biopsy from abnormal mucosa is preferable.